Firmer look to biotech fledglings gets

The Investment Column

The fledgling biotechnology sector of the stock market has had a storming rise this year, outperforming the already healthy increase of major drugs groups. But for most of the two to three years since the majority of the companies came to market, investment in the sector has been seen as something of a casino by investors - and with good reason.

British Biotech is a case in point. Seen as one of the more serious players, with a market capitalisation now well over pounds 400m, it saw its share price plunge from 590p to 428p in February after it revealed problems with clinical trials of its then most promising drug, the anti-cancer compound batimastat. Since then the shares have soared close to 900p.

This roller-coaster ride is typical of the sector, but there are signs that it is moving onto a somewhat firmer footing, with institutions showing more serious interest in investing and the product portfolio edging towards commercial exploitation.

Last Friday's news that Chiroscience had become the first of the new biotech companies to win regulatory approval - for its painkiller dexketoprofen - was something of a milestone in this respect. The decision does not necessarily mean that other companies' products will be similarly blessed by the authorities, but it does show that the industry has the potential to move from the unquantifiable "blue sky" research stage to the creation of products that have the capacity to generate sales.

British Biotech's recovery from the February debacle is also testimony to its diversification strategy. Far from proving fatal, had it been the group's only product, batimastat's starring role has now been taken by a new oral anti-cancer drug, BB-2516. Indeed, the end of this month should see the release of data on trials of BB-2516, which could have a big effect on the share price.

Given the current level of the shares, British Bio's immediate financing needs should be assured by warrants exercisable at 525p over the turn of the year, which will raise pounds 47.5m.

Celltech, another of the better-regarded members of the sector, has also been steadily building a decent development portfolio, ranging from asthma to inflammatory bowel disorders. It has also been one of the most successful at cutting the risks associated with the sector by cultivating link-ups with big groups like Zeneca and Roche.

Even Scotia, the largest of the pack and a producer of evening primrose oil, has fought off its fringe image, with the market now getting excited about its anti-cancer compounds.

But investors should remember that profits from most of these companies are unlikely to emerge much before the next century. It would be strange if, before then, some of them did not fall by the wayside.

Start your day with The Independent, sign up for daily news emails
News
ebookA unique anthology of reporting and analysis of a crucial period of history
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Guru Careers: Pricing Analyst

£30 - 35k: Guru Careers: We are seeking a Pricing Analyst to join a leading e-...

SThree: Trainee Recruitment Consultant

£20000 - £25000 per annum + OTE £45K YR1: SThree: At SThree, we like to be dif...

SThree: Trainee Recruitment Consultant

£20000 - £25000 per annum + competitive: SThree: Did you know? SThree is a mul...

Guru Careers: C# Project Team Lead

£55 - 65k (DOE): Guru Careers: A unique opportunity for a permanent C# Develop...

Day In a Page

Blundering Tony Blair quits as Middle East peace envoy – only Israel will miss him

Blundering Blair quits as Middle East peace envoy – only Israel will miss him

For Arabs – and for Britons who lost their loved ones in his shambolic war in Iraq – his appointment was an insult, says Robert Fisk
Fifa corruption arrests: All hail the Feds for riding to football's rescue

Fifa corruption arrests

All hail the Feds for riding to football's rescue, says Ian Herbert
Isis in Syria: The Kurdish enclave still resisting the tyranny of President Assad and militant fighters

The Kurdish enclave still resisting the tyranny of Assad and Isis

In Syrian Kurdish cantons along the Turkish border, the progressive aims of the 2011 uprising are being enacted despite the war. Patrick Cockburn returns to Amuda
How I survived Cambodia's Killing Fields: Acclaimed surgeon SreyRam Kuy celebrates her mother's determination to escape the US

How I survived Cambodia's Killing Fields

Acclaimed surgeon SreyRam Kuy celebrates her mother's determination to escape to the US
Stephen Mangan interview: From posh buffoon to pregnant dad, the actor has quite a range

How Stephen Mangan got his range

Posh buffoon, hapless writer, pregnant dad - Mangan is certainly a versatile actor
The ZX Spectrum has been crowd-funded back into play - with some 21st-century tweaks

The ZX Spectrum is back

The ZX Spectrum was the original - and for some players, still the best. David Crookes meets the fans who've kept the games' flames lit
Grace of Monaco film panned: even the screenwriter pours scorn on biopic starring Nicole Kidman

Even the screenwriter pours scorn on Grace of Monaco biopic

The critics had a field day after last year's premiere, but the savaging goes on
Menstrual Hygiene Day: The strange ideas people used to believe about periods

Menstrual Hygiene Day: The strange ideas people once had about periods

If one was missed, vomiting blood was seen as a viable alternative
The best work perks: From free travel cards to making dreams come true (really)

The quirks of work perks

From free travel cards to making dreams come true (really)
Is bridge the latest twee pastime to get hip?

Is bridge becoming hip?

The number of young players has trebled in the past year. Gillian Orr discovers if this old game has new tricks
Long author-lists on research papers are threatening the academic work system

The rise of 'hyperauthorship'

Now that academic papers are written by thousands (yes, thousands) of contributors, it's getting hard to tell workers from shirkers
The rise of Lego Clubs: How toys are helping children struggling with social interaction to build better relationships

The rise of Lego Clubs

How toys are helping children struggling with social interaction to build better relationships
5 best running glasses

On your marks: 5 best running glasses

Whether you’re pounding pavements, parks or hill passes, keep your eyes protected in all weathers
Joe Root: 'Ben Stokes gives everything – he’s rubbing off on us all'

'Ben Stokes gives everything – he’s rubbing off on us all'

Joe Root says the England dressing room is a happy place again – and Stokes is the catalyst
Raif Badawi: Wife pleads for fresh EU help as Saudi blogger's health worsens

Please save my husband

As the health of blogger Raif Badawi worsens in prison, his wife urges EU governments to put pressure on the Saudi Arabian royal family to allow her husband to join his family in Canada